Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice

Use of AGS-16M8F as a novel antibody drug conjugate (ADC) for treating renal cancers.

(2017) J. M. Gudas et al.   JOURNAL OF CLINICAL ONCOLOGY

MARIANNE: A phase III, randomized study of trastuzumab-DM1 (T-DM1) with or without pertuzumab (P) compared with trastuzumab (H) plus taxane for first-line treatment of HER2-positive, progressive, or recurrent locally advanced or metastatic breast cancer (MBC).

(2017) P. A. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.

(2017) Kimberly L. Blackwell et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin

(2013)   Drugs in research & development

Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays

(2012) Josée Golay et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Immunotherapy: A useful strategy to help combat multidrug resistance

(2012) Tyler J. Curiel   DRUG RESISTANCE UPDATES

Antibody–drug conjugates – a perfect synergy

(2012) John R Adair et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

(2012) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study

(2012) Christoph Mamot et al.   LANCET ONCOLOGY

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

(2012) H. K. Erickson et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Her-2+ Breast Cancer Cells with Bleomycin Immunoliposomes Linked to LLO

(2012) Max Kullberg et al.   MOLECULAR PHARMACEUTICS

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression

(2012) Daniela Frölich et al.   ARTHRITIS RESEARCH & THERAPY

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma

(2012) Frederick Lansigan   Cancer Management and Research

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

(2011) Sucheta Telang et al.   BMC CANCER

Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin

(2011) A. D. Ricart   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

(2011) M. A. Fanale et al.   CLINICAL CANCER RESEARCH

PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery

(2011) Paola Milla et al.   CURRENT DRUG METABOLISM

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer

(2011) Jacob Mathew et al.   CURRENT OPINION IN ONCOLOGY

Therapeutic potential of anticancer immunotoxins

(2011) Swati Choudhary et al.   DRUG DISCOVERY TODAY

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

(2011) Richard R. Furman et al.   LEUKEMIA & LYMPHOMA

Therapeutic Mechanism and Efficacy of the Antibody-Drug Conjugate BAY 79-4620 Targeting Human Carbonic Anhydrase 9

(2011) H. M. Petrul et al.   MOLECULAR CANCER THERAPEUTICS

New Antibody Conjugates in Cancer Therapy

(2011) Serengulam V. Govindan et al.   TheScientificWorldJOURNAL

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers

(2010) R. Hassan et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates: targeted drug delivery for cancer

(2010) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment

(2010) WW Cheng et al.   Expert Opinion on Drug Delivery

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma

(2010) H. Miles Prince et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody drug-conjugates targeting the tumor vasculature

(2010) Hans-Peter Gerber et al.   mAbs

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

(2009) Margie Gerena-Lewis et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma

(2009) Hikmat A. Al-Ahmadie et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Antibody-Drug Conjugates for the Treatment of Non-Hodgkin's Lymphoma: Target and Linker-Drug Selection

(2009) A. G. Polson et al.   CANCER RESEARCH

Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy

(2009) Mrudula Mathew et al.   CANCER SCIENCE

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

(2009) R. J. Kreitman et al.   CLINICAL CANCER RESEARCH

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

(2009) Robert J. Kreitman et al.   JOURNAL OF CLINICAL ONCOLOGY

Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial

(2009) Azra Raza et al.   LEUKEMIA & LYMPHOMA

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

(2009) M. M. Schmidt et al.   MOLECULAR CANCER THERAPEUTICS

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

(2008) Jordi Rodon et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antibody-targeted liposomes in cancer therapy and imaging

(2008) Stavroula Sofou et al.   Expert Opinion on Drug Delivery

A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck

(2008) G. C. MacDonald et al.   MEDICAL ONCOLOGY

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH